NASDAQ:BBIO

BridgeBio Pharma, Inc Earning Date

USA |NASDAQ |USD

BBIO Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-0.89 $-0.66 $-0.98
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $18.74M $54.02M $8.13M

Bridgebio Pharma, Inc's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

BBIO Earnings Date & History Chart

BBIO Earnings & Revenue Forecast

BBIO Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 8 $-0.91 $-1.18 $-0.68
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 8 $-3.65 $-4.11 $-3.26
Dec 2022 8 $-3.67 $-5.03 $-2.69

BBIO Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $-0.90 $-0.90 $-1.00
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / 1 $-3.67 $-3.68 $-3.94
Dec 2022 1 / 2 $-3.58 $-3.53 $-3.98

BBIO Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 8 $30.91M $1.19M $103.34M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 7 $110.40M $56.87M $209.23M
Dec 2022 8 $115.99M $18.52M $316.75M

BBIO Earnings Date & Revenue History

BBIO Earnings History

|
Show More
Show More

BBIO Revenue History

|
Show More
Show More

Bridgebio Pharma, Inc Next Earnings Date & Report

BBIO Next Earnings Date & Report Preview: Sep 2021 (FQ)

BBIO's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 8 analysts, the average EPS estimation for Bridgebio Pharma, Inc's next quarterly earnings is $-0.89, with a low EPS estimation of $-1.10, and a high estimation of $-0.67.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 2 downward. The EPS 1 month trend is $-0.87, the last 2 month trend is $-0.86, and the 3 month trend is $-0.88.

Based on 6 analysts, the average revenue estimation is $18.74M, with a low revenue estimation of $500.00K, and a high estimation of $51.40M.

Bridgebio Pharma, Inc Previous Earnings Dates & Reports

BBIO Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Bridgebio Pharma, Inc's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.

BBIO's earnings per share (EPS) was $-0.66, beating the consensus analysts forecast of $-0.97 by 32.11%.

The EPS was higher than the previous fiscal quarter (Mar 2021) by -44.07%, and higher than the same period a year before (Jun 2020) by -35.92%.

Revenues were $54.02M.

The company reported a net income of $-96.35M.

Free cash flow for the quarter was $-94.00M , compared to $-152.73M last quarter and $-88.19M a year before.

BBIO ended the quarter with $1.40B in total debt, an increase of 1.01% compared to the previous quarter, and an increase of 82.17% compared to the same quarter a year before.

BBIO Previous Earnings Date & Report Recap: Dec 2020 (FY)

Bridgebio Pharma, Inc's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.

BBIO's earnings per share (EPS) was $-3.80, missing the consensus analysts forecast of $-3.54 by 7.34% , and lower than the previous year's EPS (Dec 2019) by 124.85%.

Revenues were $8.25M, worse than the forecast of $24.13M by -65.81%, and down by -79.66% from previous year's revenue.

The company reported a net income of $-448.72M.

Bridgebio Pharma, Inc reported a free cash flow of $-407.23M for its fiscal year, compared to $-258.73M a year ago.

The company ended the fiscal year with $481.11M in total debt, an increase of 382.12% compared to the previous year.